Induced Pluripotent Stem Cells

Companies Induced Pluripotent Stem Cells

BlueRock Therapeutics, USA

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Th more

News Induced Pluripotent Stem Cells

• Generation of mouse induced pluripotent stem cells succeeds better without Oct4
  

  Quality of induced pluripotent stem cells is dramatically enhanced by omitting what was thought to be the most crucial reprogramming factor. Scientists at the Max Planck Institute for Molecular Biomedicine in Münster showed that Oct4, a factor most commonly used for reprogramming, is detrimental fo more

• Pluripotency or differentiation – that is the question
  

  Induced pluripotent stem cells can turn into any type of cell in the body or remain in their original form. In the current edition of Molecular Cell, scientists from the Helmholtz Zentrum München describe how cells “decide” which of these two directions to take. During their research, they identifie more

• Lab grown ‘brains’ successfully model disease
  

  Scientists were able to model a developmental disorder called neuronal heterotopia which can lead to intellectual disability and epilepsy. They used a model of brain development called brain organoids where human cells organize themselves in the petri dish into brain-like structures. Brain organoids more

Publications Induced Pluripotent Stem Cells

• Retraction: Matrix Metalloproteinase-3 in Odontoblastic Cells Derived from Ips Cells: Unique Proliferation Response as Odontoblastic Cells Derived from ES Cells

  by The PLOS ONE Editors more

• [In Depth] iPS cell therapy reported safe

  Japanese researchers reported this week that the first trial of induced pluripotent stem (iPS) cells in a human has proved safe and effective in halting the progression of age-related macular degeneration (AMD), though there was minimal improvement in vision. AMD is the leading cause of vision loss more

• Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system

  Abstract Genome editing research of human ES/iPS cells has been accelerated by clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) and transcription activator-like effector nucleases (TALEN) technologies. However, the efficiency of biallelic genetic engineeri more